Page 2 - Gb Sciences News Today

GB Sciences (OTCMKTS:GBLX – Get Rating) is one of 357 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its peers? We will compare GB Sciences to similar businesses based on the strength of its risk, valuation, institutional ownership, profitability, earnings, dividends and analyst recommendations. Profitability This table compares GB […]

/PRNewswire/ -- The "Global Central Nervous System Partnering 2016-2023: Deal trends, players and financials" report has been added to ResearchAndMarkets.coms...

GB Sciences, Inc. (OTCMKTS:GBLX – Get Rating) was the target of a large increase in short interest in April. As of April 15th, there was short interest totalling 7,400 shares, an increase of 23.3% from the March 31st total of 6,000 shares. Based on an average daily volume of 600,300 shares, the days-to-cover ratio is […]

Currently, much research is ongoing to develop new and effective therapeutic drugs for the treatment of Heart failure. The treatment of HF is dependent on angiotensin-converting enzyme inhibitor

Currently, much research is ongoing to develop new and effective therapeutic drugs for the treatment of Heart failure. The treatment of HF is dependent on...

Biopharmaceutical research company specializing in cannabis- and plant-inspired medicines shares strategic plan for 2023 and key developments from 2022LAS VEGAS, NV / ACCESSWIRE / March 7, 2023 / Gb Sciences

22.12.2022 - Gb Sciences innovative approach harnesses the power of plant-based treatments as simplified mixtures that target dangerous hyperinflammatory responses to viral infections.LAS VEGAS, Dec. 22, 2022 (GLOBE NEWSWIRE) - Gb Sciences, Inc. (OTCQB:GBLX), ... Seite 1

12.12.2022 - As mental health disorders increasingly impact global populations, Gb Sciences is developing psychotropic but non-psychedelic treatments for anxiety and depression that compete with the emerging billion-dollar psychedelic companies.LAS VEGAS, Dec. ... Seite 1

As published in the journal Food and Chemical Toxicology, the biopharmaceutical drug development firm's sponsored research used co-cultured human, primary...

At the Annual Summit, Dr. Andrea Small-Howard is presenting a Keynote Address that includes data from case studies demonstrating the utility of Gb...